GlassScriptPhysician profile
Steven J Mcclane
NPI 1770594038
$1,808.09
in general payments reported to CMS, 2019-2025
9 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.08 · 2020: $23.78 · 2021: $246 · 2022: $365 · 2023: $488 · 2024: $417 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636 · Travel and Lodging: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.94 |
| Travel and Lodging | $446.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $537.87 | 2022-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $431.25 | 2022-2025 | Eea, Signia |
| Baxter Healthcare | $239.79 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.86 | 2021-2022 | |
| Dilon Technologies, INC. | $170.11 | 2024 | Hemoblast Bellows |
| Ethicon US, LLC | $116.28 | 2019-2024 | Surgicel Nu-Knit, Echelon Circular, Evarrest |
| Davol INC. | $60.65 | 2019 | |
| Covidien LP | $18.26 | 2019 | |
| Conmed Corporation | $15.02 | 2024 | Visiclear |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mcclane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.